Price Alert

Supernus Pharmaceuticals ... (SUPN)

NASDAQ: SUPN · Real-Time Price · USD

42.17

-0.47 (-1.10%)

At close: Aug 14, 2025, 3:59 PM

42.37

0.47%

After-hours: Aug 14, 2025, 06:48 PM EDT

-1.10% (1D)

Bid	37
Market Cap	2.36B
Revenue (ttm)	665.13M
Net Income (ttm)	64.5M
EPS (ttm)	1.15
PE Ratio (ttm)	36.67
Forward PE	17.12
Analyst	Hold

Ask	44
Volume	792,354
Avg. Volume (20D)	761,388
Open	42.31
Previous Close	42.64
Day's Range	41.76 - 42.65
52-Week Range	29.16 - 43.62
Beta	0.74

About SUPN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol SUPN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for SUPN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Supernus Pharmaceuticals has released their quartely earnings on Aug 5, 2025:

Revenue of $180.92M exceeds estimates by $26.81M, with 7.48% YoY growth.

EPS of 0.4 misses estimates by -0.02, with 11.11% YoY growth.

Next Earnings Release

Supernus Pharmaceuticals Inc. is scheduled to release its earnings on Nov 3, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+13.08%

Supernus Pharmaceuticals shares are trading higher... Unlock content with Pro Subscription

5 months ago

-15.67%

Supernus Pharmaceuticals shares are trading lower after Cantor Fitzgerald downgraded the stock from Overweight to Neutral and cut its price target from $57 to $36.

News

1 week ago · zacks.com

Supernus (SUPN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare t...

1 week ago · zacks.com

Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates

Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.36 per share a year ago.

1 week ago · seekingalpha.com

Supernus Pharmaceuticals, Inc. (SUPN) Q2 2025 Earnings Call Transcript

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Jack A. Khattar - Founder, President, CEO, Secretary & Director Timothy C.

1 month ago · businesswire.com

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sage ...

2 months ago · reuters.com

Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal

Drugmaker Supernus Pharmaceuticals said on Monday it will acquire Sage Therapeutics , which makes treatments for neurological conditions, in a deal worth up to $795 million.